Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study
Open Access
- 18 November 2025
- journal article
- research article
- Published by Springer Nature in Drugs in R&D
- Vol. 25 (4) , 343-351
Abstract
Background and Objective Perampanel has been approved for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures. The oral suspension formulation benefits patients who have difficulty swallowing tablets. The unavailability of an affordable generic perampanel oral suspension formulation increased the need for a cheaper bioequivalent alternative to the marketed reference product. The study aimed to assess the bioequivalence of two formulations of perampanel oral suspension (0.5 mg/mL) administered under fasting conditions focusing on providing a cost-effective and accessible alternative to current formulations. Methods This was an open-label, two-period, two-sequence, crossover, bioequivalence study conducted under fasting conditions. Healthy subjects were randomized to receive single doses of perampanel oral suspension (12 mg), Lepsiramp and Fycompa® separated by a 6-week washout period. The maximum concentration and area under the concentration–time curve up to 72 h were the primary pharmacokinetic parameters used to assess bioequivalence. Results The geometric mean ratio of test to reference formulations and 90% confidence interval were 109.55 (99.49–120.64) for maximum concentration and 98.15 (90.68–106.23) for the area under the concentration–time curve up to 72 h, which were within the 80–125% bioequivalence range. The adverse events were mild headache and dizziness. Conclusions The two oral suspension formulations were bioequivalent, safe, and well tolerated. This provides a beneficial affordable alternative for patients requiring non-tablet oral formulations. Clinical Trial Registration The ClinicalTrials.gov registration number is NCT06969963, retrospectively registered on 13 May, 2025.Keywords
Funding Information
- Global Napi Pharmaceuticals for Global Advanced Pharmaceuticals, Egypt.
This publication has 15 references indexed in Scilit:
- A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese SubjectsClinical Drug Investigation, 2023
- Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trialsSeizure: European Journal of Epilepsy, 2022
- Aging and the Epidemiology of EpilepsyNeuroepidemiology, 2018
- Perampanel for tonic-clonic seizures in idiopathic generalized epilepsyNeurology, 2015
- The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonistEpilepsia, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305Epilepsia, 2012
- Randomized phase III study 306Neurology, 2012
- Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia, 2011
- Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935–1984Epilepsia, 1993